📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Aurobindo Pharma Faces ₹77.6 Cr GST Demand and Equal Penalty; To Appeal in GSTAT
Aurobindo Pharma has received an order from the GST Appellate Authority confirming a tax demand of ₹77.61 crore and an equivalent penalty of ₹77.61 crore. The dispute pertains to alleged excess IGST refunds and non-reversal of Input Tax Credit (ITC) for the period between July 2017 and March 2020. While the authority dropped the interest demand on ITC reversal, the primary tax and penalty were upheld. The company has already paid ₹23.72 crore under protest and intends to challenge the ruling at the GST Appellate Tribunal (GSTAT).
Key Highlights
GST demand of ₹77.61 crore confirmed along with a matching penalty of ₹77.61 crore.
Issues involve excess IGST refund (CIF vs FOB) and non-reversal of ITC under Rule 37 for FY 2017-2020.
Company has already deposited ₹23.72 crore under protest and reversed ₹8.78 crore in ITC.
Appellate Authority dropped the demand for interest on ITC reversal while upholding other charges.
Aurobindo Pharma plans to file an appeal before the Goods and Services Tax Appellate Tribunal (GSTAT).
💼 Action for Investors
Investors should monitor the outcome of the GSTAT appeal as the total potential liability exceeds ₹150 crore. While the company maintains there is no material impact, persistent tax litigation can weigh on short-term sentiment.
Aurobindo Pharma Subsidiary Unit-IV Receives VAI Status from US FDA
Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited, has received an Establishment Inspection Report (EIR) for its Unit-IV facility in Andhra Pradesh. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI), effectively closing the inspection that took place in December 2025. This follows the initial issuance of a Form 483 with 5 observations at the conclusion of the audit. The VAI classification is a positive outcome, indicating that the regulatory hurdles for this specific unit are resolved for the current cycle.
Key Highlights
US FDA inspected APL Healthcare Unit-IV from December 8 to December 17, 2025
The inspection initially resulted in a Form 483 containing 05 observations
Facility has now been classified as Voluntary Action Indicated (VAI) by the US FDA
The receipt of the EIR signifies that the regulatory inspection for this unit is now officially closed
Unit-IV is located in SPSR Nellore District, Andhra Pradesh, and is a 100% subsidiary of Aurobindo Pharma
💼 Action for Investors
Investors should view this as a positive development as it clears a regulatory hurdle for a key manufacturing unit. This reduces compliance risk and paves the way for potential new product approvals from this facility.
Aurobindo Pharma Launches Generic Pomalyst in US Targeting $3.3 Billion Market
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma, has launched Pomalidomide Capsules in the US market. The product is a generic version of BMS Pharmaceuticals' Pomalyst, which has an estimated annual market size of $3.3 billion as of January 2026. As a First-to-File (FTF) applicant, Eugia is well-positioned to capture significant market share in this high-value oncology segment. The product will be manufactured at the company's Eugia Unit-I facility, supporting its specialty portfolio growth.
Key Highlights
Launched Pomalidomide Capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths in the US
Targets a substantial US market size of approximately $3.3 billion according to IQVIA MAT data
Eugia Pharma was one of the First-to-File (FTF) ANDA applicants for this product
The product is the generic equivalent of Pomalyst by BMS Pharmaceuticals Corp
Manufacturing will be handled at the Eugia Unit-I facility
💼 Action for Investors
Investors should monitor the market share gains in the US oncology segment as this launch represents a significant revenue opportunity. The FTF status provides a competitive edge that could bolster margins in the upcoming quarters.
Aurobindo Pharma Director P. Sarath Chandra Reddy Discharged in Delhi Liquor Case
Aurobindo Pharma has confirmed that its Non-Executive Director, Mr. P. Sarath Chandra Reddy, has been discharged by a Special CBI Court in the Delhi Liquor Excise Policy case. The court found no evidence of conspiracy, illegal gratification, or unlawful benefits involving Mr. Reddy after examining material from the CBI's supplementary chargesheet dated July 29, 2024. This discharge applies to all charges leveled by the CBI, effectively removing a significant legal and reputational overhang that had persisted since late 2022. The court specifically noted a lack of basis for including him as an accused in the case.
Key Highlights
Special CBI Court discharged Mr. P. Sarath Chandra Reddy and 22 others on February 27, 2026
Court found no material evidence of participation in conspiracy or payment of illegal gratification
Mr. Reddy was originally added as Accused No. 23 in a supplementary chargesheet dated July 29, 2024
The discharge follows two months of day-to-day arguments and extensive evidence examination
The court questioned the basis on which Mr. Reddy was arrayed as an accused in the first place
💼 Action for Investors
This is a positive development as it clears a key board member from a high-profile legal controversy, reducing corporate governance concerns. Investors can now focus back on the company's fundamental performance and USFDA compliance status.
Aurobindo Pharma Subsidiary Eugia Unit-I US FDA Inspection Ends with 4 Observations
The US FDA conducted a regulatory inspection at Unit-I of Eugia Pharma Specialities Ltd, a wholly owned subsidiary of Aurobindo Pharma, between February 16 and February 27, 2026. The inspection of this formulation manufacturing facility in Telangana concluded with 4 observations. The company intends to respond to these observations within the stipulated timelines and has stated there is no immediate impact on financials or operations. Investors should monitor the classification of these observations as they can influence future product approvals from this facility.
Key Highlights
US FDA inspection of Eugia Unit-I formulation facility took place from February 16 to February 27, 2026
The inspection concluded with 4 observations issued by the regulatory authority
Eugia Pharma Specialities Ltd is a 100% wholly owned subsidiary of Aurobindo Pharma Limited
Company confirms no current quantifiable impact on financials or operations due to the observations
💼 Action for Investors
Investors should wait for the US FDA's final classification of the inspection (NAI, VAI, or OAI) to determine the severity of the 4 observations. While the company claims no immediate impact, any escalation to a Warning Letter could affect the launch pipeline from this unit.
Aurobindo Pharma Subsidiary Receives USFDA Approval for Everolimus Tablets ($78M Market)
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has received final USFDA approval for Everolimus Tablets, a generic version of Novartis' Zortress. The approved product is indicated for the prophylaxis of organ rejection in kidney and liver transplant patients. The market size for this medication is estimated at approximately US$ 78 million for the 12 months ending December 2025. This approval marks the 184th ANDA for the Eugia group, with a commercial launch planned for Q1FY27.
Key Highlights
Final USFDA approval for Everolimus Tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths.
Estimated annual market size of US$ 78 million according to IQVIA MAT December 2025 data.
Commercial launch is expected to commence in Q1FY27 from the Eugia Unit-I facility.
Represents the 184th ANDA approval for the Eugia Pharma Specialities Group.
Product is bioequivalent and therapeutically equivalent to the reference drug Zortress by Novartis.
💼 Action for Investors
Investors should monitor the timely launch in Q1FY27 as this adds to Aurobindo's specialty portfolio in the US market. The approval reinforces the company's execution capabilities in the complex generics and specialty segment through its subsidiary Eugia.
Aurobindo Pharma Incorporates New Subsidiary Engenra Biologics for CDMO Expansion
Aurobindo Pharma has incorporated a new wholly-owned subsidiary, Engenra Biologics Private Limited, in India on February 24, 2026. The subsidiary is established with an initial cash subscription of Rs. 10 lakhs, representing 1,00,000 equity shares at Rs. 10 each. The primary objective of this new entity is to expand the company's contract manufacturing (CDMO) and other pharmaceutical manufacturing operations. This move signals Aurobindo's intent to scale its specialized manufacturing capabilities within the domestic market.
Key Highlights
Incorporation of Engenra Biologics Private Limited as a 100% wholly-owned subsidiary
Initial capital investment of Rs. 10 lakhs divided into 1,00,000 equity shares
Strategic focus on expanding contract manufacturing and pharmaceutical operations
Entity incorporated in India with 100% control and no prior turnover history
Transaction conducted at arms-length with no promoter group interest
💼 Action for Investors
Investors should monitor the scale of capital expenditure and future contract wins under this new subsidiary as it indicates Aurobindo's growth trajectory in the CDMO space. The stock remains a watch for long-term expansion in specialized manufacturing.
Aurobindo Pharma Receives ₹169.84 Crore GST Demand and Penalty Order
Aurobindo Pharma has been served with four orders from the GST Department demanding the recovery of ₹169.84 crores in previously granted refunds. The demand includes ₹84.92 crores in GST and an equivalent penalty of ₹84.92 crores for the period of September to December 2022. The dispute involves the calculation of Input Tax Credit (ITC) refunds for its EOU Unit 3, which the department alleges were erroneous. The company intends to contest this demand through an appeal, stating that there is no material impact on its current operations.
Key Highlights
Total disputed amount stands at ₹169.84 crores, including a 100% penalty of ₹84.92 crores.
The orders allege erroneous refund of accumulated ITC under Rule 89 of CGST Rules for late 2022.
The dispute centers on whether domestic market values of similar goods should limit export refund amounts.
Aurobindo Pharma is challenging the validity of Rule 89(4)(C) in the Telangana High Court.
The company will file a fresh appeal before the Commissioner of Central Tax (Appeals), Hyderabad.
💼 Action for Investors
Investors should monitor the legal proceedings as tax disputes are common in the sector; however, the immediate financial impact is limited given the company's scale. No immediate action is required as the company is actively contesting the demand.
Aurobindo Pharma Clarifies USFDA Inspection at Unit-VII Following Media Reports
Aurobindo Pharma has issued a clarification to the stock exchanges regarding news reports of USFDA quality concerns at its Telangana-based Unit-VII. The company confirmed that the USFDA inspection at this facility concluded on February 10, 2026, and they are currently preparing a response to the observations within the stipulated timelines. Management maintains that these inspections are a routine part of global business operations and that all material information has already been disclosed. The stock had previously reacted to reports of these quality concerns, prompting the exchange's request for verification.
Key Highlights
USFDA inspection at Unit-VII (Telangana) was completed on February 10, 2026
Company responded to NSE and BSE clarification requests on February 18, 2026
Management committed to responding to USFDA observations within the required regulatory timeframe
Company asserts that no additional material information remains undisclosed beyond the February 10 filing
💼 Action for Investors
Investors should wait for details regarding the specific nature and severity of the USFDA observations (Form 483) for Unit-VII. The stock is likely to remain under pressure or volatile until the regulatory risk is fully quantified.
Aurobindo Pharma Q3 FY26: Revenue Up 8.4% to ₹8,646 Cr, Europe Growth Surges 27%
Aurobindo Pharma reported a steady Q3 FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 crores, driven by a robust 27% growth in the European business. EBITDA margins remained healthy at 20.5%, supported by lower raw material costs and a favorable business mix. The company is on track for its Pen-G plant ramp-up, targeting over 10,000 metric tonnes annually, and expects its European operations to surpass the $1 billion mark by the end of FY26. Management clarified that recent USFDA observations at the Eugia III facility are procedural and will not impact production.
Key Highlights
Consolidated revenue increased 8.4% YoY to ₹8,646 crores with EBITDA at ₹1,773 crores (20.5% margin)
European formulation business grew 27% YoY to ₹2,703 crores, nearing a $1 billion annual run rate
US injectable sales rose 17% YoY, while overall US revenue stood at $420 million
Pen-G facility ramp-up is on track to reach 65-70% capacity by March 2026
Net profit reached ₹910 crores, despite a one-time ₹65 crore charge for labor code amendments
💼 Action for Investors
Investors should monitor the ramp-up of the Pen-G facility and the commercialization of the Dayton plant in FY27 as key margin drivers. The stock remains a strong play on geographic diversification, particularly with the outperformance in Europe.
Aurobindo Pharma Subsidiary Receives US FDA Approval for ADQUEY Ointment
Aurobindo Pharma's step-down subsidiary, Acrotech Biopharma, has secured US FDA approval for ADQUEY (difamilast 1%) ointment. This non-steroidal treatment is indicated for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older. The approval is backed by Phase III clinical trials showing significant improvement in patients over a 4-week treatment period compared to a placebo. This marks a strategic milestone for Aurobindo as it expands its proprietary medication portfolio in the high-value US dermatology market.
Key Highlights
FDA approval granted for ADQUEY (difamilast 1%) for treating mild-to-moderate atopic dermatitis.
Indicated for both adults and pediatric patients as young as 2 years old.
Product is a novel, non-steroidal, topical phosphodiesterase 4 (PDE4) inhibitor.
Phase III trials demonstrated Investigator’s Global Assessment (IGA) success within 4 weeks of treatment.
Acrotech Biopharma has held the US license for this Otsuka Pharmaceutical-developed drug since 2021.
💼 Action for Investors
Investors should view this as a positive development that strengthens Aurobindo's specialty branded portfolio in the US. Monitor the commercial launch timeline and market penetration, as branded products typically offer higher margins than generic counterparts.
Aurobindo Pharma Unit-VII Receives US FDA Form 483 with 9 Procedural Observations
The US FDA concluded an inspection of Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing facility in Telangana, on February 10, 2026. The inspection, which began on January 28, resulted in the issuance of a Form 483 with 9 observations. Management has characterized these observations as procedural in nature and stated there is no immediate impact on financial or operational activities. The company is preparing a formal response to be submitted within the stipulated regulatory timelines.
Key Highlights
US FDA inspection conducted at Unit-VII oral solid dosage facility from January 28 to February 10, 2026.
Form 483 issued by the regulator containing a total of 9 observations.
Company management confirms all 9 observations are procedural in nature.
No immediate quantifiable financial or operational impact reported by the company.
Unit-VII is located at the Special Economic Zone (Pharma) in Jedcherla, Telangana.
💼 Action for Investors
Investors should monitor the final classification of the inspection by the US FDA, as 9 observations is a significant count even if procedural. Watch for updates on whether the facility receives Voluntary Action Indicated (VAI) or Official Action Indicated (OAI) status.
Aurobindo Pharma Q3FY26: Revenue up 8.4% to ₹8,646 Cr, EBITDA Margins steady at 20.5%
Aurobindo Pharma reported a steady Q3FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 crore, primarily driven by a robust 27.4% surge in the European market. EBITDA rose 9% YoY to ₹1,773 crore with margins remaining stable at 20.5%, supported by operational efficiencies and stable gross margins. While US revenues remained stable at $420 million, the company generated strong free cash flows of $118 million during the quarter. The company maintains a healthy net cash position of $251 million even after accounting for the Khandelwal Labs acquisition.
Key Highlights
Consolidated revenue grew 8.4% YoY to ₹8,646 crore, led by a 27.4% growth in Europe formulations to ₹2,703 crore.
Net Profit increased by 7.6% YoY to ₹910 crore, while EBITDA margins improved slightly to 20.5%.
US business remained stable with 9 product launches and 7 approvals, contributing 43.2% of total revenue.
R&D investment stood at ₹409 crore (4.7% of sales), focusing on biosimilars and specialty products.
Net cash position reached $251 million as of December 2025, after appropriating cash for the Khandelwal Labs acquisition.
💼 Action for Investors
Investors should focus on the company's successful diversification into European markets and its strong cash generation. Monitor the progress of the biosimilar pipeline (CuraTeQ) as the filing for Denosumab has seen a slight delay to mid-2026.
Aurobindo Pharma to Acquire 26% Stake in Garuda Renewables for ₹66 Crores
Aurobindo Pharma has approved an investment of ₹66 crores to acquire a 26% stake in Garuda Renewables Private Limited, a special purpose vehicle for hybrid wind and solar power. This strategic move includes a Power Purchase Agreement to procure renewable energy for the company's operations. The investment is designed to achieve substantial long-term savings in power costs while significantly improving the company's ESG profile through reduced carbon emissions. The transaction is expected to be completed within six months, subject to regulatory approvals.
Key Highlights
Investment of ₹66 crores to acquire up to 26% equity stake in Garuda Renewables Private Limited.
Strategic shift to hybrid wind and solar energy procurement via a long-term Power Purchase Agreement.
Target entity is a subsidiary of Ecoren Energy, which has a 5GW commissioned/under-construction track record.
Expected completion timeline of 6 months for the acquisition process.
Aims to reduce operational power costs and enhance the company's green energy commitment.
💼 Action for Investors
Investors should view this as a positive step toward operational efficiency and ESG compliance. While the immediate financial impact is small relative to Aurobindo's size, the long-term power cost savings will support margin stability.
Aurobindo Pharma Appoints Dr. Punita Kumar-Sinha as Independent Director for 3-Year Term
Aurobindo Pharma has appointed Dr. (Mrs.) Punita Kumar-Sinha as an Additional Non-Executive Independent Director for a three-year term effective February 9, 2026. Dr. Kumar-Sinha is a seasoned global investor and former Senior Managing Director at Blackstone Asia Advisors, bringing over 30 years of capital markets experience. Simultaneously, Dr. (Mrs.) Deepali Pant Joshi will step down from the board on February 10, 2026, following the completion of her two-year tenure. This board refresh adds significant expertise in governance, ESG, and investment management to the company.
Key Highlights
Dr. (Mrs.) Punita Kumar-Sinha appointed as Independent Director for a 3-year term ending February 8, 2029.
The new appointee is a former Senior Managing Director and CIO at Blackstone Asia Advisors with a PhD from Wharton.
Dr. (Mrs.) Deepali Pant Joshi ceases to be a Director effective February 10, 2026, after completing a 2-year term.
Dr. Kumar-Sinha holds a Chemical Engineering degree from IIT Delhi and is a CFA charterholder.
The appointment is subject to the approval of the company's members.
💼 Action for Investors
Investors should view this as a positive development for corporate governance, as the new director brings high-caliber global investment and ESG expertise. No immediate action is required, but the move strengthens the board's oversight capabilities.
Aurobindo Pharma Q3 FY26 Net Profit Rises 7.6% to ₹910 Cr; Europe Revenue Surges 27%
Aurobindo Pharma reported a steady Q3 FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 Cr, primarily driven by a robust 27.4% growth in the European market. Net profit increased by 7.6% YoY to ₹910 Cr, despite a one-time impact of ₹65 Cr related to new labor code costs. The US business saw modest growth of 2.2%, while the API segment faced a slight decline of 4.3% YoY. The company maintains a strong financial position with a net cash surplus of $251 million and generated free cash flows of $118 million during the quarter.
Key Highlights
Revenue from operations grew 8.4% YoY to ₹8,646 Cr, led by Europe and ARV segments.
Europe formulations revenue jumped 27.4% YoY to ₹2,703 Cr, now contributing 31.3% of total revenue.
EBITDA margin (before Forex and Other Income) remained stable at 20.5% compared to 20.4% in the previous year.
Net profit reached ₹910 Cr, including a one-time ₹65 Cr provision for labor code changes.
Strong balance sheet with $251 million net cash and 7 new USFDA ANDA approvals received during the quarter.
💼 Action for Investors
Investors should note the strong momentum in the European market which is successfully offsetting slower growth in the US and API segments. The healthy cash position and consistent R&D investment support long-term growth prospects.
Aurobindo Pharma Q3FY26 Net Profit Rises 7.6% to ₹910 Cr; Revenue Up 8.4% at ₹8,646 Cr
Aurobindo Pharma reported a steady Q3FY26 performance with consolidated revenue growing 8.4% YoY to ₹8,646 crore, primarily driven by a robust 27.4% growth in the Europe segment. EBITDA margins remained healthy at 20.5%, supported by stable gross margins and operational efficiencies. The company maintained a strong net cash position of $251 million even after accounting for the Khandelwal Labs acquisition. While the US market saw modest 2.2% growth, the biosimilar pipeline under CuraTeQ is progressing with key filings planned for 2026.
Key Highlights
Consolidated Revenue increased 8.4% YoY to ₹8,646 crore, with Europe business growing 27.4% to ₹2,703 crore.
EBITDA grew 9.0% YoY to ₹1,773 crore with a margin of 20.5%, up 11 bps from the previous year.
Net Profit attributable to owners rose 7.6% YoY to ₹910 crore, resulting in an EPS of ₹15.67.
Strong balance sheet with a net cash position of US$ 251 million and free cash flow generation of $118 million in Q3.
R&D investment stood at ₹409 crore (4.7% of sales), focusing on biosimilars and specialty products.
💼 Action for Investors
Investors should monitor the company's successful diversification into the European market and the upcoming regulatory filings for its biosimilar pipeline in 2026. The strong cash position and stable margins make it a solid pick in the large-cap pharma space.
Aurobindo Pharma Q3 Consolidated PAT Rises 7.6% YoY to ₹9,098 Million
Aurobindo Pharma reported a steady performance for Q3 FY26, with consolidated revenue from operations growing 8.4% YoY to ₹86,459 million. Net profit for the quarter stood at ₹9,098 million, up from ₹8,455.7 million in the same period last year, despite an exceptional charge of ₹653.3 million related to new labor code provisions. The company's performance was bolstered by a significant 21.7% reduction in finance costs compared to the previous year. For the nine-month period, the company has maintained a stable profit level of ₹25,821.3 million.
Key Highlights
Consolidated Revenue from operations increased by 8.4% YoY to ₹86,459 million.
Consolidated Profit After Tax (PAT) grew by 7.6% YoY to ₹9,098 million.
Finance costs decreased significantly by 21.7% YoY to ₹927.7 million from ₹1,184.8 million.
An exceptional item of ₹653.3 million was recorded due to the implementation of new Labour Codes affecting employee benefits.
Basic EPS improved to ₹15.67 for the quarter compared to ₹14.56 in the previous year's corresponding quarter.
💼 Action for Investors
Investors should take note of the steady revenue growth and the significant reduction in interest expenses which indicates better debt management. The stock remains a key pharmaceutical play, though the non-recurring impact of labor code adjustments should be factored into margin expectations.
Aurobindo Pharma Q3 FY26 Revenue Up 8.4% YoY to ₹8,646 Cr; Invests ₹66 Cr in Renewable Energy
Aurobindo Pharma reported a consolidated revenue of ₹8,645.9 crore for Q3 FY26, an 8.4% increase compared to ₹7,978.5 crore in the same quarter last year. Standalone Profit After Tax (PAT) showed strong growth, rising to ₹582.1 crore from ₹472.1 crore YoY. The company is strategically investing ₹66 crore for a 26% stake in Garuda Renewables to secure hybrid wind and solar power. Furthermore, the board approved the merger of its vaccine and biologics subsidiaries to streamline its specialized portfolio.
Key Highlights
Consolidated revenue from operations grew 8.4% YoY to ₹86,459 million in Q3 FY26.
Standalone Profit After Tax (PAT) increased 23.3% YoY to ₹5,820.7 million.
Approved ₹66 crore investment for a 26% stake in Garuda Renewables Private Limited for hybrid energy procurement.
Board approved the merger of Auro Vaccines Private Limited into Curateq Biologics Private Limited to consolidate operations.
Recognized a non-recurring exceptional item of ₹173.8 million related to the enactment of new Labour Codes.
💼 Action for Investors
Investors should view the steady revenue growth and the strategic shift toward renewable energy for cost optimization as positive signs. The consolidation of biologics and vaccine arms suggests a focused approach to high-growth segments, warranting a 'Hold' or 'Accumulate' stance.
Aurobindo Pharma's Eugia Unit III Receives 11 US FDA Observations
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Ltd., completed a US FDA inspection at its Unit III formulation facility in Telangana. The inspection, which took place from January 27 to February 06, 2026, concluded with 11 observations. The company has characterized these observations as procedural in nature and plans to respond within the stipulated timeframe. While the company reports no immediate financial impact, the double-digit count of observations requires careful monitoring for potential regulatory escalation.
Key Highlights
US FDA inspection conducted at Eugia Pharma's Unit III facility from January 27 to February 06, 2026
The inspection concluded with a total of 11 observations issued by the regulator
Management has classified the observations as procedural rather than systemic or data integrity issues
The company stated there is no immediate impact on current financial or operational activities
A formal response to the observations will be submitted to the US FDA within the required timeline
💼 Action for Investors
Investors should monitor the final classification of the inspection by the US FDA, as 11 observations is a relatively high number that could delay new product approvals if not resolved quickly. Maintain a watch on whether the facility receives a Voluntary Action Indicated (VAI) or Official Action Indicated (OAI) status.